Indication and efficacy of adjuvant chemotherapy with oral fluoropyrimidines for Dukes' B colorectal cancer

Anticancer Research

Volumn 26, Issue 4 B, 2006, Pages 3089-3093

  Yoshimatsu, Kazuhiko ^a   Umehara, Arihiro ^a   Ishibashi, Keiichiro ^a   Yokomizo, Hajime ^a   Yoshida, Kiyohito ^a   Fujimoto, Takashi ^a   Watanabe, Kiyo ^a   Ogawa, Kenji ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Adjuvant chemotherapy; Colorectal cancer; Fluoropyrimidines

Indexed keywords

FLUOROPYRIMIDINE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER RECURRENCE; CANCER RESEARCH; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDICATION; FEMALE; HUMAN; LIVER CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEROSA; SURVIVAL RATE; TREATMENT INDICATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PYRIMIDINES; RETROSPECTIVE STUDIES; TEGAFUR; URACIL;

EID: 33746669354     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Macdonald JS and Astrow AB: Adjuvant therapy of colon cancer. Semin Oncol 28: 30-40, 2001.
2. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen CM, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, Veeder MH and Mailliard JA: Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 122: 321-326, 1995.
3. Brown ML, Nayfield SG and Shibley LM: Adjuvant therapy for stage III colon cancer: economics returns to research and cost-effectiveness of treatment. J Natl Cancer Inst 86: 424-430, 1994.
4. Lourie JA, Moertel CG, Fleming TR, Wieand HS, Leigh JE, Rubin J, WcCormmack GW, Gerstner JB, Krook JE, Malliard J, Twito DI, Morton RF, Tschetter LK and Barlow JF: Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. J Clin Oncol 7: 1447-1456, 1989.
5. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen CM, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, Veeder MH and Mailliard JA: Intergroup study of fluorouracil plus levamisole as adjuvant therapy for Stage II/Dukes' B2 colon cancer. J Clin Oncol 13: 2936-2943, 1995.
6. Mamounas E, Wieand S, Wolmark N, Bear HD, Atkins JN, Song K, Jones J and Rockette H: Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four national surgical adjuvant breast and bowel project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 17: 1349-1355, 1999.
7. The International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPCT B2) Investigators: Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol 17: 1356-1363, 1999.
8. Malcahy HE, Toner M, Patchett SE, Daly L and O'Donoghue DP: Identifying stage B colorectal cancer patients at high risk of tumor recurrence and death. Dis Colon Rectum 40: 326-331, 1997.
9. Lindmark G, Gerdin B, Sundberg C, Pahlman L, Bergstrom R and Glimelius B: Prognostic significance of microvascular count in colorectal cancer. J Clin Oncol 14: 461-466, 1996.
10. Nori D, Merimsky O, Samala E, Saw D, Cortes E, Chen E and Turner JW: Tumor ploidy as a risk factor for disease recurrence and short survival in surgically-treated Dukes' B2 colon cancer patients. J Surg Oncol 59: 239-242, 1995.
11. Benson AB III, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, Krzyzanowska MK, Maroun J, McAllister P, Van Cutsem E, Brouwers M, Charette M and Haller DG: American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22: 3408-3419, 2004.
12. Swanson RS, Compton CC, Stewart AK and Bland KI: The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined. Ann Surg Oncol 10: 65-71, 2003.
13. Di Fabio F, Nascimbeni R, Villanacci V, Baronchelli C, Bianchi D, Fabbretti G, Casella C and Salerni B: Prognostic variables for cancer-related survival in node-negative colorectal carcinomas. Dig Surg 20: 128-133, 2004.
14. Burdy G, Panis Y, Nemeth J, Lavergne-Slove A and Valler P: Identifying patients with T3-T4 node-negative colon cancer at high risk of recurrence. Dis Colon Rectum 44: 1692-1688, 2001.
15. Willette CG, Badizadegan K, Ancukiewicz M and Shellito PC: Prognostic factors in stage T3N0 rectal cancer: do all patients require postoperative pelvic irradiation and chemotherapy? Dis Colon Rectum 41: 167-173, 1999.
16. Figueredo A, Charette ML, Maroun J, Brouwers MC and Zuraw L: Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group. J Clin Oncol 22: 3395-3407, 2004.
17. Mulcahy HE, Toner M, Path MR, Patchett SE, Daly L and O'Donoghue DP: Identifying stage B colorectal cancer patients at high risk of tumor recurrence and death. Dis Colon Rectum 40: 326-331, 1997.
18. Merkel S, Wein A, Gunther K, Papadopoulos T, Hohenberger W and Hermanek P: High-risk group of patients with stage II colon carcinoma. Cancer 92: 1435-1443, 2001.
19. Newland RC, Dent OF, Chapuis PH and Bokey L: Survival after curative resection of lymph node negative colorectal carcinoma. Cancer 76: 564-571, 1995.
20. Caplin S, Cerottini JP, Bosman FT, Constanda MT and Givel JC: For patients with Dukes' B (TNM stage II) colorectal carcinoma, examination of six or fewer lymph node is related to poor prognosis. Cancer 83: 666-672, 1998.
21. Onate-Ocana LF, Montesdeoca R, Lopez-Graniel CM, Aiello-Crocifoglio V, Mondragon-Sanchez R, Cortina-Borja M, Herrera-Goepfert R, Oros-Ovalle C and Gallardo-Rincon D: Identification of patients with high-risk lymph node-negative colorectal cancer and potential benefit from adjuvant chemotherapy. Jpn J Clin Oncol 34: 323-328, 2004.
22. Lanza G, Gafa R, Santini A, Maestri I, Dubini A, Gilli G and Cavazzini L: Prognostic significance of DNA ploidy in patients with stage II and stage III colon carcinoma: a prospective flow cytometric study. Cancer 82: 49-59, 1998.
23. Cascinu S, Ligi M, Graziano F, Del Ferro E, Valentini M, Grianti C, Bartolucci M and Catalane G: S-phase fraction can predict event-free survival in patients with pT2-T3N0M0 colorectal carcinoma. Cancer 83: 1081-1085, 1998.
24. Lanza G, Matteuzzi M, Gafa R, Orvieto E, Maestri I, Santini A and Del Senno L: Chromosome 18q allelic loss and prognosis in stage II and III colon cancer. Int J Cancer 79: 390-395, 1998.
25. Jen J, Kim H, Piantadosi S, Liu ZF, Levitt RC, Sistonen P, Kinzler KW, Vogelstein B and Hamilton SR: Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 331: 213-221, 1994.
26. Graziano F and Cascinu S: Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: how much evidence is enough? Ann Oncol 14: 1026-1038, 2003.
27. Japanese Society for Cancer of the Colon and Rectum: General Rules for Clinical and Pathological Studies on Cancer of the Colon, Rectum and Anus, Sixth Edition. Kanehara Ltd., Tokyo, 1998.
28. Moertel CG, Fleming TR, MacDonald JS, Haller DG, Laurie JA, Goodman PG et al: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322: 352-358, 1990.
29. Mitomi T, Tsuchiya S and Iijima N: Cooperative Study Group of Surgical Adjuvant Immunochemotherapy for Cancer of Colon and Rectum. Randomized controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer. Dis Colon Rectum 35: 123-130, 1992.
30. Sakamoto J, Hamada C, Kodaira S, Nakazato H and Ohashi Y: Adjuvant therapy with oral fluoropyrimidines as main chemotherapeutic agents after curative resection for colorectal cancer: individual patient data meta-analysis of randomized trials. Jpn J Clin Oncol 29: 78-86, 1999.
31. Smith RE, Colangelo L, Wieand HS, Begovic M and Wolmark N: Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01. J Natl Cancer Inst 96: 1128-1132, 2004.
32. Benson AB III, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, Krzyzanowska MK, Maroun J, McAllister P, Van Cutsem E, Brouwers M, Charette M and Haller DG: American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22: 3408-3419, 2004.
33. Sakamoto J, Ohashi Y, Hamada C, Buyse M, Burzykowski T and Piedbois P: Meta-Analysis Group of the Japanese Society for Cancer of the Colon and Rectum: Meta-Analysis Goup in Cancer. Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials. J Clin Oncol 22: 484-492, 2004.